| 债券代码：113660 | 债券简称：寿 转债 | | --- | --- | | | 22 | | 证券代码：603896 | 证券简称：寿仙谷 公告编号：2026-005 | 浙江寿仙谷医药股份有限公司 二、"寿 22 转债"本次转股情况 "寿 22 转债"转股期自 2023 年 5 月 23 日至 2028 年 11 月 16 日止。自 2023 年 5 月 23 日至 2026 年 3 月 31 日，"寿 22 转债"累计转股金额为 311,000 元，占"寿 22 转债"发行总量的 0.0781%；累计因转股形成的股份数量为 8,150 股，占"寿 22 转债"转股前公司已发行股份总额的 0.0041%。 关于"寿 22 转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、"寿 22 转债"发行上市概况 经中国证券监督管理委员会"证监许可[2022]2165 号"文核准，公司于 2022 年 11 月 17 日公开发行 398 万张可转换公司债券，每张面值 100 ...

浙江寿仙谷医药股份有限公司 关于增加签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江寿仙谷医药股份有限公司（以下简称"公司"）于2025年4月17日召开 第四届董事会第二十八次会议，审议通过了《关于续聘公司2025年度审计机构的 议案》，同意继续聘请立信会计师事务所（特殊普通合伙）（以下简称"立信事务 所"）作为公司2025年度审计机构，负责公司财务报告审计、内部控制审计以及 其他相关审计工作。具体内容详见公司于2025年4月18日在上海证券交易所网站 （www.see.com.cn）发布的《寿仙谷续聘会计师事务所公告》（公告编号： 2025-020）。 近日，公司收到立信事务所发来的《关于浙江寿仙谷医药股份有限公司审计 机构增加签字注册会计师的函》。现将有关情况公告如下： | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2026-004 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 刘翘苇，20 ...

| 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 转债 22 | | 浙江寿仙谷医药股份有限公司 关于"寿 22 转债"预计满足转股价格向下修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）转股价格修正条款 根据公司《募集说明书》相关条款规定，"在本次发行的可转换公司债券存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价低 于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交公 司股东会表决。上述方案须经出席会议的股东所持表决权的三分之二以上通过方 可实施。股东会进行表决时，持有本次发行的可转换公司债券的股东应当回避。 修正后的转股价格应不低于本次股东会召开日前二十个交易日公司股票交易均 价和前一交易日均价之间的较高者。若在前述三十个交易日内发生过转股价格调 整的情形，则在转股价格调整日前的交易日按调整前的转股价格和收盘价计算， 在转股价 ...

Core Viewpoint - The article discusses the recent decline in the A-share storage chip market, highlighting the impact of Google's new compression algorithm, TurboQuant, on memory demand and the overall storage industry outlook [1][3][5]. Group 1: Market Performance - On March 27, A-share storage chips experienced a collective decline, with companies like Baiwei Storage dropping over 6% at one point, and other firms such as Jiangbolong and Zhaoyi Innovation also seeing declines of over 3% [1][2]. - The storage index showed significant drops across various companies, with Jiangbolong at -3.73%, Zhongdian Port at -3.31%, and Baiwei Storage at -3.01% [2]. Group 2: Technological Developments - Google introduced TurboQuant, a compression algorithm aimed at reducing memory requirements for AI systems, particularly addressing key-value cache bottlenecks [3][4]. - TurboQuant can compress key-value caches to 3-bit precision without retraining models, achieving approximately 6 times memory compression while maintaining model accuracy [3][4]. Group 3: Industry Outlook - Despite the recent market downturn, the long-term demand for storage chips remains strong, driven by increased investments in AI infrastructure by overseas CSPs, which is expected to boost enterprise storage demand [5]. - Analysts predict that the current storage cycle's intensity and sustainability may surpass the previous cycle, with significant profit increases for related industry chain companies [5]. - Supply constraints are expected to persist until at least the second half of 2027, despite major DRAM manufacturers planning production increases of about 26% for DRAM and 24% for NAND by 2026 [5].

Industry Overview - The Chinese medicine industry is entering a new evidence-driven cycle following the release of the Basic Drug Directory Management Measures, which emphasizes the integration of clinical value, insurance payment capabilities, and tiered diagnosis and treatment systems [8][10] - The market performance of the Chinese medicine sector showed a decline of 1.75% in the week before the holiday, which was the largest drop among the pharmaceutical sub-sectors [3][4] Market Performance - The Chinese medicine sector's PE (ttm) was 27X, down 0.49X from the previous period, while the PB (lf) was 2.27X, down 0.04X, indicating a relative valuation position within historical ranges [5] - The overall pharmaceutical sector index closed at 8282.27 points, down 0.81%, with only the medical services sector showing an increase of 0.22% [3] Upstream Market Dynamics - The market demand for Chinese medicinal materials has increased ahead of the holiday, leading to a slight rise in the price index, which reached 229.02 points, up 0.1% from the previous week [6][7] Regulatory Changes - The revised Basic Drug Directory Management Measures highlight a "balanced approach to Chinese and Western medicine," establishing a strict negative list for market entry and emphasizing clinical value and dynamic adjustments [9] - The new measures are expected to accelerate structural differentiation in the short term and favor leading companies with clinical evidence and strong innovation capabilities in the long term [8][10] Investment Recommendations - The report maintains an "overweight" rating for the industry, suggesting three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Price governance will lead to clearer differentiation within the industry, with companies that have competitive advantages likely to benefit from price-volume trade-offs [12] - The recovery of consumption driven by macroeconomic improvement and increased health awareness among the aging population is expected to boost sales of consumer-oriented Chinese medicines [13] - State-owned enterprises in the Chinese medicine sector are anticipated to benefit from reforms aimed at improving efficiency and performance [13] Target Companies - Recommended companies include Zoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [13]

Core Viewpoint - The establishment of a standard system is crucial for the internationalization of traditional Chinese medicine (TCM), providing a pathway for core products to enter overseas markets and allowing Shouxiangu (寿仙谷) to find a differentiated breakthrough in this process [1] Group 1: International Standardization Efforts - Shouxiangu has led and participated in the formulation of over 100 TCM-related standards, including 8 international standards, with 5 already published, using standardization as a tool to promote TCM's internationalization [1][2] - The company shifted its focus to international standardization after facing challenges with registering TCM as pharmaceuticals abroad, such as long approval cycles and high clinical costs [2] - The ISO international standards for Lingzhi and Dendrobium, initiated in 2011, were officially published between 2018 and 2019 and are now applied in 31 countries and regions, including the US, Canada, Australia, and Germany [2] Group 2: Key Developments in Standardization - The ISO international standard for broken-wall Lingzhi spore powder, set to be implemented by July 2025, fills a gap in global quality specifications for this product, establishing key parameters and safety limits [3] - The inclusion of Ganoderic acid A as a core quality evaluation index in the standards reflects the differentiation of raw materials and the transformation of quality characteristics into internationally recognized technical language [3] Group 3: Technological Foundation and R&D - Shouxiangu positions itself as a technology-driven enterprise, investing in all aspects of the industry chain, including breeding, cultivation, processing, and product development, to ensure product safety and effectiveness [4] - The company has developed a standardized system for the entire TCM industry chain, successfully breeding 12 new varieties of medicinal materials and obtaining multiple patents for its purification technology [4] - R&D expenses reached 9.79% of revenue in the first three quarters of 2025, an increase of 3.15 percentage points year-on-year, with the number of R&D personnel growing to 179, accounting for 16.1% of the total workforce [4] Group 4: Business Performance and Market Strategy - In the third quarter of 2025, Shouxiangu achieved revenue of 130 million yuan, a year-on-year increase of 8.51%, with online channel revenue growing by 11.80% and its share of total revenue rising from 18.97% to 23.92% [6] - The company is expanding its product line and targeting younger consumers, launching new products like Dendrobium pomelo juice and various snacks, with a focus on affordability and appealing packaging [6] - Shouxiangu is also prioritizing the cultivation of saffron, having successfully bred two new varieties with high active ingredient content, and is advancing related evidence-based medical research [6]

Core Viewpoint - The establishment of a standard system is crucial for the internationalization of traditional Chinese medicine (TCM), providing a pathway for core products to enter overseas markets and allowing Shouxiangu to find a differentiated breakthrough in the internationalization process [1] Group 1: International Standardization - Shouxiangu has led and participated in the formulation of over 100 TCM-related standards, including 8 international standards, with 5 already published [1] - The company initiated the ISO international standardization work for TCM products like Ganoderma and Dendrobium in 2011, facing initial challenges in the proposal process, which took several years to gain approval [2] - The ISO standards for Ganoderma and Dendrobium were officially published between 2018 and 2019 and are now applied in 31 countries and regions, including the US, Canada, Australia, and Germany [2] - The ISO standard for broken-wall Ganoderma spore powder, set to be implemented by July 2025, fills a global gap in quality specifications [2] Group 2: Quality Control and Research - The inclusion of Ganoderma acid A as a core quality evaluation index reflects the differentiation of raw materials and the transformation of quality characteristics into internationally recognized technical language [3] - Shouxiangu emphasizes a technology-driven approach across the entire industry chain, ensuring product safety, effectiveness, and stability through a standardized system [3] - The company has developed 12 new varieties of medicinal materials and holds multiple invention patents for its purification technology [3] Group 3: Financial Performance and R&D - In the first three quarters of 2025, Shouxiangu's R&D expense ratio reached 9.79%, an increase of 3.15 percentage points year-on-year, with R&D personnel accounting for 16.1% of the total workforce [4] - The project "Key Technology Innovation and Application of the Whole Industry Chain of Edible and Medicinal Fungi," co-led by Shouxiangu, won the National Science and Technology Progress Award [4] Group 4: Market Strategy and Product Development - In Q3 2025, Shouxiangu achieved revenue of 130 million yuan, a year-on-year increase of 8.51%, with online channel revenue growing by 11.80% [4] - The company is expanding its product line and targeting younger consumers by launching new products like "Dendrobium Pomelo Juice" and various snacks, which are positioned as everyday consumer goods [5][6] - The focus on younger demographics is evident in the design and pricing of new products, which aim to attract urban consumers seeking "light health" solutions [6]

Core Viewpoint - The company, Shouxiangu (603896), has provided insights into its R&D expenses as a percentage of revenue for the years 2021 to 2024, indicating a stable trend without a year-on-year decline [1] Group 1: R&D Expenses Overview - For the years 2021 to 2024, the R&D expenses as a percentage of revenue are projected to be 6.33%, 5.77%, 6.33%, and 7.00% respectively [1] - In the period from January to September 2024, the R&D expenses as a percentage of revenue are reported to be 9.79%, which is considered a normal fluctuation [1] - The company emphasizes that there has not been a trend of decreasing R&D expenses year-on-year, as confirmed by its previous periodic reports [1]

Group 1 - The company disclosed a related party transaction plan for 2026, involving the procurement of goods worth 20 million yuan and sales of goods worth 6.2 million yuan, which requires shareholder approval and may impact operations [2] - The company is not currently investing in short videos or short dramas but is promoting its brand through platforms like Douyin and WeChat, while its parent company is involved in the film "Unbreakable" [3] - The company has experienced continuous net outflows of main funds since early January 2026, potentially due to market style rotation and short-term pressure on the traditional Chinese medicine sector [4] Group 2 - The company is expanding its market presence outside Zhejiang Province, focusing on fast-moving consumer goods development and digital empowerment as part of its long-term strategy [5] - The traditional Chinese medicine industry is driven by aging demographics and policy support, but there are risks associated with deepening centralized procurement policies and fluctuations in raw material costs [6]

Core Viewpoint - Shouxiangu (603896) has not yet engaged in external investments related to short videos and short dramas, focusing instead on brand promotion and product sales through new media platforms like Douyin, WeChat Video, and Xiaohongshu [1] Group 1 - The company is currently leveraging new media platforms for brand promotion and product sales [1] - Future strategies will involve a careful assessment of the collaborative value of various new media formats in brand building and market education [1] - The company aims to promote the innovative dissemination of traditional Chinese medicine culture [1] Group 2 - A new romantic film titled "Unbreakable" produced by the company's parent, Zhejiang Shouxiangu Investment Management Co., has been released on iQIYI [1] - The film is produced by Zhang Jizhong, who serves as both the producer and director [1] - Investors are encouraged to watch the film [1]